Skip to content

Mitochondria · Longevity

MOTS-c

A mitochondrial-derived peptide with genuinely interesting biology and thin translational data.

L2PreclinicalExperimental / researchPreclinicalVery low confidenceLast reviewed 2026-08-23
SC injection· unapproved

Also known as: mitochondrial ORF of the 12S rRNA type-c

Evidence passport

Last reviewed 2026-08-23

Evidence level
L2Preclinical
Confidence
Very low confidence
Human efficacy
20/100
Human safety
12/100
Regulatory status
Experimental / research
Development
Preclinical
Routes
SC injection· unapproved
Evidence base
Mostly preclinical
Furthest stage
Not established
Source curation
Sources fully curated
Clinical maturity
Preclinical with early translational human observation

Most of this evidence comes from animals and cells

The supporting research for MOTS-c is predominantly preclinical (Level 1–2). That is a legitimate starting point for science and a poor basis for personal decisions. Human results are not simply a scaled-up version of mouse results.

Overview

Human evidence20/100
Preclinical evidence70/100
Human safety evidence12/100

Clinical maturity: Preclinical with early translational human observation

Routes & formulations

Marketed / research routes — never approved

SC injection· unapproved

No approved formulation exists. Material sold online is typically injectable; route-specific efficacy and safety in humans are unstudied.

Route availability is not evidence of efficacy, and evidence from one route does not transfer to another. The Registry never provides dosing or sourcing information.

Peptide lifecycle

  1. Discovery

  2. Preclinical

  3. Phase I

  4. Phase II

  5. Phase III

  6. Approved

PreclinicalFurthest stage not established in our curated record

Early translational research only; no established clinical development programme.

What it is

A short peptide encoded within mitochondrial DNA that appears to act as a metabolic signalling molecule between mitochondria and the nucleus.

What people claim

  • Reverses age-related metabolic decline
  • Improves insulin sensitivity and exercise capacity
  • Extends healthspan

What the evidence actually says

The biology is genuinely compelling: MOTS-c looks like a real endogenous exercise-and-metabolism signal, and circulating levels associate with metabolic status in human observational work. What is missing is the bit that matters clinically — randomised human trials of administering it. Interesting is not the same as proven.

Human evidence

  • Observational studies associating circulating MOTS-c with age, fitness and metabolic status.
  • No robust randomised controlled trials of exogenous administration.

Preclinical evidence

  • Rodent studies showing improved insulin sensitivity and exercise capacity.
  • Cell work on AMPK activation and metabolic stress responses.

Animal and cell findings are Level 1–2 evidence.

Mechanism and pathways

  • Activates AMPK, shifting cells toward energy production and glucose uptake.
  • Translocates to the nucleus under metabolic stress to influence gene expression.
  • Interacts with the folate-methionine one-carbon cycle.

Safety and unknowns

  • Essentially no human safety data for administered MOTS-c.
  • Long-term consequences of chronic AMPK-axis manipulation are unknown.

Cancer relevance

Theoretical / mechanistic concern only

AMPK signalling has context-dependent roles in cancer biology — sometimes tumour-suppressive, sometimes supportive of stress survival. This is a mechanistic unknown, not a demonstrated risk or benefit in humans.

Regulatory status

Not an approved medicine. Research compound; also prohibited in sport. The FDA's 503A Category 2 list flags MOTS-c as a bulk substance raising significant safety risks for compounding.

Evidence grade

L2PreclinicalVery low confidence

Animal, organoid or tissue studies. Mice are not tiny humans.

What would change our rating?

  • A published Phase 1 human safety and pharmacokinetic study.
  • Randomised trials in metabolic endpoints.

References and sources

Sources fully curated

Source hierarchy: regulatory documents and trial registries first, peer-reviewed work next, sponsor material flagged as non-independent. We never use supplier or clinic marketing as evidence, and where a verified source has not yet been curated we say so rather than inventing one.

Evidence change history

  1. 2026-06-28

    Baseline entry: classified as promising-but-unproven rather than emerging therapy.

    L2PreclinicalBaseline entry
    Human data are observational. Without a published trial of exogenous administration, therapeutic claims cannot rise above Level 2.

Related claims we’ve checked

Promising but unprovenL2PreclinicalLongevity

“MOTS-c is a proven longevity therapy.”

Promising but unproven — great biology, missing trials.

  • Human observational work links circulating MOTS-c with fitness and metabolic status.
  • Rodent studies show metabolic improvements, but no randomised human trial of administration exists.
  • 'Promising' is a compliment about the science, not a recommendation to inject it.
Last reviewed 2026-06-28Compound profile